Affimed to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, will have its CEO, Dr. Adi Hoess, present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 8:00 a.m. Eastern Time. The presentation will be available via a live webcast on Affimed’s website and accessible for 30 days post-event. Affimed focuses on innovative therapies to empower patients against cancer, currently developing AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma, and AFM24 for advanced EGFR-expressing solid tumors. For further details, visit www.affimed.com.

Argus Session date unavailable

-1.27% session move Open Argus

Details

News Market Reaction – AFMD

The recorded move for AFMD in the trading session of this news was -1.27%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Heidelberg, Germany, May 28,  2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 8:00 a.m. Eastern Time. 

A live webcast of the presentation can be accessed under the “Investors” section of Affimed’s website at https://www.affimed.com/investors/webcasts_cp/ and will be available for 30 days following the event. 

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.   

Affimed Investor Contact

Alexander Fudukidis, Head of Investor Relations
E-Mail: IR@affimed.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Affimed's CEO present at the Jefferies Virtual Healthcare Conference?

Affimed's CEO, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 8:00 a.m. Eastern Time.

How can I access the live webcast of Affimed's presentation?

The live webcast of Affimed's presentation can be accessed under the 'Investors' section of their website at www.affimed.com/investors/webcasts_cp/.

What is the focus of Affimed's clinical development?

Affimed is focused on developing therapies that utilize their ROCK® platform for treating hematologic and solid tumors, particularly AFM13 and AFM24.

What are the specific studies Affimed is currently enrolling patients in?

Affimed is enrolling patients in a registration-directed study for AFM13 targeting CD30-positive relapsed/refractory peripheral T cell lymphoma, and a Phase 1/2a study for AFM24 targeting advanced EGFR-expressing solid tumors.